Find information on thousands of medical conditions and prescription drugs.

Flomax

Tamsulosin is the generic name for a medicine (usually sold as "Flomax"), which is commonly used as an alpha blocker, particularly to treat the syptoms of benign prostatic hypertrophy (BPH)—enlargement of the male prostate gland.

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Boehringer, Abbott to co-promote Flomax - Brief Article
From Drug Store News, 9/27/99

Boehringer Ingelheim Pharmaceuticals and Abbott Laboratories have announced a collaboration to distribute and co-promote Flomax, Boehringer Ingelheim's drug for the treatment of benign prostatic hyperplasia treatment. The companies plan substantially increased and aggressive promotional efforts for the drug, which had a 30 percent market share in the first half of 1999. Promotional efforts will include a new and ongoing DTC campaign, both television and print, and increased pharmacist education initiatives in a stated effort to achieve 20 percent annual growth for Flomax over the next five years.

Abbott, which currently markets the category leader, Hytrin (terazosin HCl) for BPH, will begin to promote and sell Flomax following the anticipated introduction of a generic terazosin to the U.S. market. Boehringer is hoping to take advantage of Abbott's experience and marketing reach in the BPH category, a market estimated at $500 million.

COPYRIGHT 1999 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group

Return to Flomax
Home Contact Resources Exchange Links ebay